FI945081A0 - Stabiili hydratoitu kefalosporiinikuivajauhe oraaliseen suspensioformulaatioon - Google Patents

Stabiili hydratoitu kefalosporiinikuivajauhe oraaliseen suspensioformulaatioon

Info

Publication number
FI945081A0
FI945081A0 FI945081A FI945081A FI945081A0 FI 945081 A0 FI945081 A0 FI 945081A0 FI 945081 A FI945081 A FI 945081A FI 945081 A FI945081 A FI 945081A FI 945081 A0 FI945081 A0 FI 945081A0
Authority
FI
Finland
Prior art keywords
dry powder
oral suspension
pct
suspension formulation
cephalosporin
Prior art date
Application number
FI945081A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI945081A (fi
Inventor
Donald A Johnson
Lorraine Wearley
Rebecca Galeos
Joel A Sequeira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI945081A publication Critical patent/FI945081A/fi
Publication of FI945081A0 publication Critical patent/FI945081A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
FI945081A 1992-04-30 1994-10-28 Stabiili hydratoitu kefalosporiinikuivajauhe oraaliseen suspensioformulaatioon FI945081A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87688192A 1992-04-30 1992-04-30
PCT/US1993/003856 WO1993021923A1 (en) 1992-04-30 1993-04-30 Stable hydrated cephalosporin dry powder for oral suspension formulation

Publications (2)

Publication Number Publication Date
FI945081A FI945081A (fi) 1994-10-28
FI945081A0 true FI945081A0 (fi) 1994-10-28

Family

ID=25368763

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945081A FI945081A0 (fi) 1992-04-30 1994-10-28 Stabiili hydratoitu kefalosporiinikuivajauhe oraaliseen suspensioformulaatioon

Country Status (23)

Country Link
US (1) US5599557A (cs)
EP (1) EP0642344B1 (cs)
JP (1) JP3378004B2 (cs)
KR (1) KR100257803B1 (cs)
AT (1) ATE150310T1 (cs)
AU (1) AU674516B2 (cs)
CA (1) CA2134467A1 (cs)
CZ (1) CZ283428B6 (cs)
DE (1) DE69309052T2 (cs)
DK (1) DK0642344T3 (cs)
EE (1) EE03039B1 (cs)
ES (1) ES2099438T3 (cs)
FI (1) FI945081A0 (cs)
GR (1) GR3023516T3 (cs)
HK (1) HK1002407A1 (cs)
HU (1) HU215958B (cs)
NO (1) NO307594B1 (cs)
NZ (1) NZ252433A (cs)
PL (1) PL171630B1 (cs)
RU (1) RU2123863C1 (cs)
SK (1) SK279329B6 (cs)
UA (1) UA27899C2 (cs)
WO (1) WO1993021923A1 (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
AU2004258944B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007502296A (ja) * 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
US8062672B2 (en) * 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1701705A4 (en) * 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp IMPROVED ABSORPTION OF MODIFIED RELEASE DOSAGE FORMS
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US8999395B2 (en) 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
EP2172223B1 (en) * 2007-06-22 2020-12-16 Kaneka Corporation Composition containing physiologically active substance
EP2186789B1 (en) * 2007-08-22 2013-12-25 Kaneka Corporation Method of producing reduced coenzyme q10 and method of stabilizing the same
WO2011139253A2 (en) 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
RU2550932C1 (ru) * 2014-03-18 2015-05-20 Александр Александрович Кролевец Способ получения нанокапсул цефалоспориновых антибиотиков в ксантановой камеди

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549746A (en) * 1967-11-02 1970-12-22 Bristol Myers Co Antibiotic composition
US3780195A (en) * 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
NZ220764A (en) * 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US4803082A (en) * 1987-10-28 1989-02-07 Warner-Lambert Company Flavor and sweetness enhancement delivery systems and method of preparation
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation

Also Published As

Publication number Publication date
US5599557A (en) 1997-02-04
ATE150310T1 (de) 1997-04-15
CZ263694A3 (en) 1995-04-12
CZ283428B6 (cs) 1998-04-15
ES2099438T3 (es) 1997-05-16
RU94046038A (ru) 1996-11-10
WO1993021923A1 (en) 1993-11-11
EP0642344B1 (en) 1997-03-19
HK1002407A1 (en) 1998-08-21
DE69309052D1 (de) 1997-04-24
EE03039B1 (et) 1997-10-15
GR3023516T3 (en) 1997-08-29
KR950701224A (ko) 1995-03-23
FI945081A (fi) 1994-10-28
JP3378004B2 (ja) 2003-02-17
KR100257803B1 (en) 2000-08-01
PL171630B1 (pl) 1997-05-30
AU674516B2 (en) 1997-01-02
RU2123863C1 (ru) 1998-12-27
AU4115293A (en) 1993-11-29
SK279329B6 (sk) 1998-10-07
HU215958B (hu) 1999-03-29
HUT71226A (en) 1995-11-28
NO944113D0 (no) 1994-10-28
SK131194A3 (en) 1995-07-11
EP0642344A1 (en) 1995-03-15
HU9403108D0 (en) 1995-02-28
UA27899C2 (uk) 2000-10-16
NO307594B1 (no) 2000-05-02
NO944113L (no) 1994-10-28
CA2134467A1 (en) 1993-11-11
JPH07506366A (ja) 1995-07-13
DK0642344T3 (da) 1997-07-07
NZ252433A (en) 1996-07-26
DE69309052T2 (de) 1997-06-19

Similar Documents

Publication Publication Date Title
FI945081A0 (fi) Stabiili hydratoitu kefalosporiinikuivajauhe oraaliseen suspensioformulaatioon
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
MY101791A (en) New benzimidazole derivatives
HUT37418A (en) Process for producing new 2,2'-imino-bis/ethanol/ derivatives and pharmaceutical compositions sontaining them as active agents
ES8608864A1 (es) Un procedimiento para producir un preparado a modo de hojas
IL72854A0 (en) 1-heteroaryl-4-((2,5-pyrrolidine-dion-1-yl)alkyl)piperazine derivatives,their preparation and pharmaceutical compositions containing them
IL84944A (en) Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
DE3783356D1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
BG105275A (en) Tan-1057 derivatives
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
ES8504774A1 (es) Procedimiento para preparar derivados de 2-piperacinil-quinazolina
HU9302813D0 (en) Pharmaceutical compositions containing new benzimidazole derivatives and process for preparing the active ingredients
DE3268487D1 (en) 2,3,4-trinor-m-inter-phenylene-prostaglandin derivatives, their preparation and pharmaceutical compositions
HUT42099A (en) Process for preparing 2,3-diamino-2,3-dideoxy-hexose derivatives and pharmaceutical compositions containing thereof as active substances
ATE145647T1 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen
FR2541114B1 (fr) Compositions pharmaceutiques antifongiques utilisables par voie orale contenant de l'omoconazole
IL64989A (en) 4,5-diphenyl-2-aminoethoxyphenyl imidazole derivatives,their preparation and pharmaceutical compositions containing them
ES8401483A1 (es) Procedimiento para preparar nuevas furobenzazepinas.
IL64641A (en) 4-aminoalkyl-1,3-dihydro 2(2h)-indolone derivatives,process for their preparation and pharmaceutical compositions containing them
JO1653B1 (en) The current benzimidazole is a therapeutically active method for preparing it
IL66892A0 (en) 7 beta-aminooxazolylacetamino-3-cephem-4-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
IL84129A (en) Bis(2,2-dialkylalkanoyl)-3-(4-trialkylbenzyl)-1-piperazinyl)-rifamycin s derivatives,their preparation and pharmaceutical compositions containing them